Pharmacological Treatment for Stage C HFrEF: Soluble Guanylyl Cyclase Stimulators e317ĭevice and Interventional Therapies for HFrEF e318 7.4.1. Pharmacological Treatment for Stage C HFrEF: Digoxin e316 Management of Stage C HF: Ivabradine e316 GDMT Dosing: Sequencing and Uptitration e313Īdditional Medical Therapies e316 7.3.9.1. Hydralazine and Isosorbide Dinitrate e308ĭrugs of Unproven Value or That May Worsen HF e311 Sodium-Glucose Cotransporter 2 Inhibitors e307 Mineralocorticoid Receptor Antagonists (MRAs) e306 Renin-Angiotensin System Inhibition With ACEi or ARB or ARNi e302 Pharmacological Treatment for HFrEF e302 7.3.1. Management of Stage C HF: Activity, Exercise Prescription, and Cardiac Rehabilitation e300ĭiuretics and Decongestion Strategies in Patients With HF e301 Nonpharmacological Interventions e297 7.1.1. Management of Stage B: Preventing the Syndrome of Clinical HF in Patients With Pre-HF e295 Patients at Risk for HF (Stage A: Primary Prevention) e292 Stage A (Patients at Risk for HF) e292 5.1.
#BOSCH AL 1450 DV MANUAL DEXTERITY SERIAL#
Initial and Serial Evaluation: Clinical Assessment: HF Risk Scoring e291 Wearables and Remote Monitoring (Including Telemonitoring and Device Monitoring) e289Įxercise and Functional Capacity Testing e290 Use of Biomarkers for Prevention, Initial Diagnosis, and Risk Stratification e282 Initial Laboratory and Electrocardiographic Testing e281 Organization of the Writing Committee e268Ĭlass of Recommendation and Level of Evidence e270Ĭlassification of HF by Left Ventricular Ejection Fraction (LVEF) e275ĭiagnostic Algorithm for Classification of HF According to LVEF e277Ĭlinical Assessment: History and Physical Examination e279 4.1.1. Tamis-Holland, MD, FAHA, FACCįormer Joint Committee member current member during the writing effort. O’Gara, MD, MACC, FAHA, Immediate Past Chair ¶
0 kommentar(er)
